-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For a long time, new drugs have been characterized by difficult design, high cost, and time-consuming.
On average, the industry’s previous research and development of a new drug required "10 years and 1 billion US dollars
.
" In this context, in recent years, as the research and development of new drugs has become more and more popular, and the cost of research and development has continued to rise, in order to reduce investment pressure, pharmaceutical companies have begun to use AI platforms to conduct drug research and development cases
.
Recently, reports have shown that Jingxin Pharmaceutical and AI drug research and development company Jingtai Technology have reached a project cooperation to jointly promote the research and development of small molecule antidepressant drugs
.
It is reported that in this cooperation, the two parties will focus on the research and development of innovative small-molecule antidepressant drugs with independent intellectual property rights, and apply AI technology to the design, optimization and verification of preclinical drug candidates for this project, and accelerate the development of drugs urgently needed by patients with depression
.
Specifically, the cooperation between Jingxin Pharmaceutical and Jingtai Technology will use Jingtai Technology’s first integrated artificial intelligence drug discovery platform to target the three-dimensional structure characteristics of depression disease-related targets and use AI molecules to generate, structure-based Drug design and other methods generate specific molecular libraries with structural diversity, and high-precision binding energy evaluation methods and a variety of ADMET prediction models for molecular screening to obtain outstanding properties including activity, selectivity, druggability, and safety, and novel frameworks In order to solve the common problems of existing antidepressant treatment programs, such as ineffective treatment, high recurrence, slow onset of action, and side effects
.
In addition, before this, Simcere Pharmaceuticals and Almai Biotechnology have also jointly announced that the two parties have signed an exclusive license agreement for the new anti-tumor drug ALM005
.
According to the data, Almai Bio is a technology-based company that uses artificial intelligence drug screening and optimization technology to accelerate the development of new drugs, focusing on data-driven, using machine learning models to carry out lead compound design and discovery, drug multi-target selectivity, and optimized drug properties.
.
The ALM005 of this cooperation is based on Al Vein's AI technology and discovered very valuable compound molecules
.
In addition to the above pharmaceutical companies, the use of AI to accelerate innovation is already very common in the industry
.
It is worth mentioning that, in addition to the current acceleration of pharmaceutical companies in the AI drug research and development track, the domestic capital market has also paid great attention to AI pharmaceuticals
.
According to incomplete statistics, up to now, there have been more than 15 investment and financing events in the domestic AI pharmaceutical industry
.
For example, Conmadison (Beijing) announced the completion of a Pre-A round of tens of millions of yuan in financing
.
Funds raised in this round are mainly used in areas such as the development of innovative small molecule drug platforms based on the three-dimensional structure of proteins and the research and development of computationally-driven new drugs
.
Jingtai Technology also announced that it has completed a new round of D round of financing of 400 million US dollars, with a post-investment valuation of more than 13 billion yuan
.
The industry believes that, on the whole, the development of the AI new drug research and development industry has begun to usher in an active period
.
In the future, affected by the general trend of the industry, AI new drug research and development will obtain more new breakthroughs, and the innovation results of local pharmaceutical companies may continue to accelerate
.
On average, the industry’s previous research and development of a new drug required "10 years and 1 billion US dollars
.
" In this context, in recent years, as the research and development of new drugs has become more and more popular, and the cost of research and development has continued to rise, in order to reduce investment pressure, pharmaceutical companies have begun to use AI platforms to conduct drug research and development cases
.
Recently, reports have shown that Jingxin Pharmaceutical and AI drug research and development company Jingtai Technology have reached a project cooperation to jointly promote the research and development of small molecule antidepressant drugs
.
It is reported that in this cooperation, the two parties will focus on the research and development of innovative small-molecule antidepressant drugs with independent intellectual property rights, and apply AI technology to the design, optimization and verification of preclinical drug candidates for this project, and accelerate the development of drugs urgently needed by patients with depression
.
Specifically, the cooperation between Jingxin Pharmaceutical and Jingtai Technology will use Jingtai Technology’s first integrated artificial intelligence drug discovery platform to target the three-dimensional structure characteristics of depression disease-related targets and use AI molecules to generate, structure-based Drug design and other methods generate specific molecular libraries with structural diversity, and high-precision binding energy evaluation methods and a variety of ADMET prediction models for molecular screening to obtain outstanding properties including activity, selectivity, druggability, and safety, and novel frameworks In order to solve the common problems of existing antidepressant treatment programs, such as ineffective treatment, high recurrence, slow onset of action, and side effects
.
In addition, before this, Simcere Pharmaceuticals and Almai Biotechnology have also jointly announced that the two parties have signed an exclusive license agreement for the new anti-tumor drug ALM005
.
According to the data, Almai Bio is a technology-based company that uses artificial intelligence drug screening and optimization technology to accelerate the development of new drugs, focusing on data-driven, using machine learning models to carry out lead compound design and discovery, drug multi-target selectivity, and optimized drug properties.
.
The ALM005 of this cooperation is based on Al Vein's AI technology and discovered very valuable compound molecules
.
In addition to the above pharmaceutical companies, the use of AI to accelerate innovation is already very common in the industry
.
It is worth mentioning that, in addition to the current acceleration of pharmaceutical companies in the AI drug research and development track, the domestic capital market has also paid great attention to AI pharmaceuticals
.
According to incomplete statistics, up to now, there have been more than 15 investment and financing events in the domestic AI pharmaceutical industry
.
For example, Conmadison (Beijing) announced the completion of a Pre-A round of tens of millions of yuan in financing
.
Funds raised in this round are mainly used in areas such as the development of innovative small molecule drug platforms based on the three-dimensional structure of proteins and the research and development of computationally-driven new drugs
.
Jingtai Technology also announced that it has completed a new round of D round of financing of 400 million US dollars, with a post-investment valuation of more than 13 billion yuan
.
The industry believes that, on the whole, the development of the AI new drug research and development industry has begun to usher in an active period
.
In the future, affected by the general trend of the industry, AI new drug research and development will obtain more new breakthroughs, and the innovation results of local pharmaceutical companies may continue to accelerate
.
